U.S. Pharmaceuticals & Biotech Most Popular Stocks

Eagle Pharmaceuticals

Market Cap: US$36.8m

A pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States.

Senti Biosciences

Market Cap: US$36.6m

A clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases.

Akari Therapeutics

Market Cap: US$36.5m

An oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins.

Sonnet BioTherapeutics Holdings

Market Cap: US$36.4m

A biotechnology company, owns a platform for biologic medicines of single or bifunctional action.

Mural Oncology

Market Cap: US$36.2m

Operates as a clinical-stage oncology company that focuses on discovering and developing immunotherapies for the treatment of patients with cancer.

CollPlant Biotechnologies

Market Cap: US$36.0m

A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.

IGC Pharma

Market Cap: US$35.9m

A clinical stage pharmaceutical company, develops treatments for Alzheimer’s disease in the United States and Colombia.

Mersana Therapeutics

Market Cap: US$35.8m

A clinical-stage biopharmaceutical company, develops antibody-drug conjugates (ADC) for cancer patients with unmet needs.

Bioqual

Market Cap: US$35.8m

Provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States.

Rani Therapeutics Holdings

Market Cap: US$34.4m

Operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States.

OnKure Therapeutics

Market Cap: US$34.4m

A clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers.

AN2 Therapeutics

Market Cap: US$33.9m

A biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics.

International Isotopes

Market Cap: US$33.8m

Manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, sodium iodide I-131 drug product, and radiochemicals for clinical research and life sciences in the United States and internationally.

Adaptimmune Therapeutics

Market Cap: US$33.7m

A commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom.

Iterum Therapeutics

Market Cap: US$33.2m

A pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States.

Lunai Bioworks

Market Cap: US$32.5m

A pre-clinical stage biotechnology company, engages in the development of pharmaceutical and biological products for the treatment of cancer and HIV in the United States and the Netherlands.

Oncotelic Therapeutics

Market Cap: US$32.1m

A clinical-stage biopharmaceutical company, engages in the development of drugs for the treatment of orphan oncology indications.

Harvard Apparatus Regenerative Technology

Market Cap: US$31.6m

A clinical-stage biotechnology company, focuses on developing regenerative-medicine treatments for disorders of the gastro-intestinal system and other organs resulting from cancer, trauma, or birth defects.

Revium Rx

Market Cap: US$31.6m

A pre-clinical stage biopharmaceutical company, develops nano-liposomal particles (NLP) based pharmaceutical candidates.

Angion Biomedica

Market Cap: US$30.1m

Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for chronic and progressive fibrotic diseases in the United States.

LakeShore Biopharma

Market Cap: US$30.1m

A biopharmaceutical company, discovers, develops, manufactures, commercializes, and sells vaccines and therapeutic biologics for infectious diseases and cancer.

Lexaria Bioscience

Market Cap: US$29.9m

Operates as a biotechnology company.

NeuroSense Therapeutics

Market Cap: US$29.6m

A clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally.

Klotho Neurosciences

Market Cap: US$29.3m

Develops medicines for the treatment of cancer, cardiovascular, and neurodegenerative disorders.

Cadrenal Therapeutics

Market Cap: US$29.1m

Operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions.

Evaxion

Market Cap: US$28.6m

A clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.

Rein Therapeutics

Market Cap: US$27.8m

A biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States.

Kezar Life Sciences

Market Cap: US$27.5m

A clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases in the United States.

Daré Bioscience

Market Cap: US$27.4m

Develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States.

Genvor

Market Cap: US$26.9m

Develops plant-based defense technology designed to help farmers achieve global food security.

ProText Mobility

Market Cap: US$25.9m

A biotech company, engages in the development of pharmaceutical botanical medicines.

Boundless Bio

Market Cap: US$25.3m

A clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA).

MIRA Pharmaceuticals

Market Cap: US$24.8m

Operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders.

Exicure

Market Cap: US$24.8m

Does not have significant operations.

Enlivex Therapeutics

Market Cap: US$24.6m

Operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel.

Passage Bio

Market Cap: US$24.4m

A genetic medicines company, develops gene therapies for central nervous system diseases.